In hematological malignancies, polymorphisms restricted only to IL-1β and IL-18 were associated with clinical and pathophysiological characteristics in AML and chronic myeloid leukemia (CML) (75, 76). This evidence concerns the gene IL1B and chronic myelogenous leukemia, BCR-ABL1 positive.